Arcadia Biosciences, INC 8-K filings

Arcadia Biosciences discloses a discretionary bonus for CEO Thomas J. Schaefer for the 2025 fiscal year, alongside updated compensation details and the date for its 2026 annual meeting.

Arcadia Biosciences has closed a $4 million private placement of pre-funded warrants and investment options to institutional investors.

Arcadia Biosciences, Inc. has dismissed Deloitte & Touche LLP as its independent auditor and appointed Ramirez Jimenez International CPAs (RJI) as its successor.

Arcadia Biosciences announced its fourth-quarter and full-year 2025 financial results, highlighting Zola revenue growth, reduced operating expenses, and the termination of a proposed business combination.

Two directors, Albert D. Bolles, Ph.D., and Deborah Carosella, have resigned from Arcadia Biosciences' Board, effective February 4, 2026.

Arcadia Biosciences secured approximately $2.1 million in gross proceeds by inducing investors to exercise existing preferred investment options at a reduced price, issuing new options as an incentive.

Arcadia Biosciences announced the termination of its proposed all-stock business combination with Roosevelt Resources, prompting a renewed search for strategic alternatives.

Arcadia Biosciences, Inc. announced the results of its annual stockholder meeting, including the election of Class I directors and advisory approval of executive compensation.

Arcadia Biosciences reports mixed Q3 2025 results with Zola revenue growth and strong margins, but faces merger timing uncertainty due to a federal government shutdown.

Arcadia Biosciences announced its 2025 annual meeting will be held on December 19, 2025, and updated the deadline for shareholder nominations and proposals.

Arcadia Biosciences announced the resignation of CFO Mark Kawakami, the appointment of CEO Thomas J. Schaefer as interim CFO, and provided an update on its all-stock merger with Roosevelt Resources.

Arcadia Biosciences reported an 11% increase in second-quarter revenues driven by Zola coconut water sales, but net loss widened significantly due to a $4.5 million credit loss on a note receivable.

Arcadia Biosciences reports a default on a $6 million promissory note from Above Food Corp. due to a missed payment and potential implications for a pending merger with Roosevelt Resources, LP.

Arcadia Biosciences announces a 22% increase in revenue for Q1 2025, fueled by a 90% surge in Zola coconut water sales and strategic asset monetization.

Arcadia Biosciences and Roosevelt Resources amend their Securities Exchange Agreement, extending the termination date to August 15, 2025, and adjusting share issuance terms.

Arcadia Biosciences enters into an agreement to regain intellectual property rights and receive $750,000 while transferring certain patents to a third party.

Arcadia Biosciences announces a 56% increase in Q4 revenue and a business combination with Roosevelt Resources, highlighting growth in Zola coconut water sales and strategic asset sales.

Arcadia Biosciences will combine with Roosevelt Resources in an all-stock transaction, resulting in a shift in ownership and a change of company name and focus.

Arcadia Biosciences will combine with Roosevelt Resources in an all-stock transaction, marking a shift from agricultural innovation to oil and gas exploration and production.

Arcadia Biosciences announced an 18% year-over-year increase in total revenue for the third quarter of 2024, fueled by a 55% surge in Zola coconut water sales and a 68% expansion in Zola's retail distribution.

Arcadia Biosciences has amended its previous 8-K filing to include detailed compensation information for newly appointed CEO Thomas J. Schaefer and CFO Mark Kawakami, effective July 5, 2024.

Arcadia Biosciences saw a significant improvement in its second-quarter financial results, driven by strategic asset sales and increased sales of Zola coconut water.

Arcadia Biosciences has appointed its current CEO, Thomas J. Schaefer, to its Board of Directors, filling a vacancy created by a recent resignation.

Arcadia Biosciences has announced the resignation of its CEO, Stanley Jacot Jr., and the appointment of Thomas J. Schaefer as the new CEO, effective July 5, 2024.

Arcadia Biosciences held its annual meeting on June 25, 2024, where shareholders elected directors, ratified the appointment of auditors, approved an amendment to the equity incentive plan, and gave an advisory vote on executive compensation.

Arcadia Biosciences has finalized the sale of its GoodWheat business to Above Food Corp for a total consideration of $4 million, including a promissory note and cash transfer.

Arcadia Biosciences has sold and licensed its resistant starch durum wheat trait assets to Pioneer Hi-Bred International for $4 million in cash.

Arcadia Biosciences announced positive first quarter 2024 results, highlighted by revenue growth, reduced operating expenses, and the lowest loss from continuing operations in six years.

Arcadia Biosciences announced its fourth quarter and full year 2023 financial results, highlighting gross profit growth and reduced operating expenses.

Arcadia Biosciences has announced the resignation of its Chief Marketing Officer, Laura Pitlik, effective March 1, 2024, and approved retention bonuses for its CEO and CFO.